ODE-1 Director Unger, Not Medical Officer, Conducted Epidiolex Safety Review
Highly unusual move of an ODE director leading clinical review of a drug had nothing to do with public sentiment regarding Epidiolex's derivation from marijuana, US FDA says; Unger instead wanted to use the review as an example for future reviews to rely more on the agency's analyses rather than those of applicants.
You may also be interested in...
Eric Bastings will lead Division of Neurology I, which is expected to handle Biogen’s Alzheimer’s drug aducanumab and Sarepta’s refiling of golodirsen for DMD next year.
The approval for the GW Pharmaceuticals drug covers the treatment of Lennox-Gastaut syndrome and Dravet syndrome, two forms of rare and severe childhood epilepsy – the US agency was quick to clarify what the approval did not cover, chiefly marijuana.
GW Pharmaceuticals’ cannabis-derived epilepsy drug gets unanimous panel endorsement, affirming US FDA's belief that there are no obstacles to approval.